“Medicine is a field where you don't need to squint to see the benefits of AI. It's your mom, it's your dad, it's your sister, it's your brother. And it's the doctors who will care for them in their most vulnerable moments.” Yesterday, during the UN General Assembly, we announced a partnership with @AnthropicAI to make OpenEvidence available free of charge to physicians in low- and middle-income countries, placing life-saving medical AI into the hands of physicians worldwide, regardless of the economics.

"Access to medical knowledge shouldn't depend on geography," said Daniel Nadler, founder and CEO of OpenEvidence. That's why OpenEvidence and @AnthropicAI are bringing a specialized version of OpenEvidence, free, to clinicians in about 100 low- and middle-income countries, including Uganda, Angola, Sudan, Haiti, and Mongolia. More here:

Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence have partnered to bring cutting-edge AI and precision oncology expertise closer to the point of care. By integrating OpenEvidence into MSK's Epic workflow and embedding MSK's @OncoKB™ precision oncology knowledge base directly into OpenEvidence, clinicians can access trusted, evidence-based insights within their existing clinical workflows. “We're excited that OpenEvidence will widen OncoKB's reach, bringing MSK's expert interpretation of a patient's unique cancer genetics to cancer care providers across the U.S. to help them make molecularly informed treatment decisions,” says Dr. Debyani Chakravarty (@CDebyaniPhD), a lead scientist for OncoKB at MSK. Learn more about this new collaboration:

Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter. “AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK. Full press release:

Memorial Sloan Kettering opening its precision oncology data to physicians nationwide through OpenEvidence. Today's Forbes has the story. @MSKCancerCenter has spent years building the world's most detailed map of which cancer mutations respond to which treatments. Until now, you had to be treated at MSK to benefit from it. Soon, an oncologist in a small practice in Montana will see the same evidence as a subspecialist in Manhattan, at the moment it matters, for the patient in front of them. More patients getting the right treatment the first time, wherever they live. Read full article here

Canada, this one’s for you. “This partnership with OpenEvidence represents an important step in ensuring Canadian physicians have access to cutting-edge clinical decision support tools. By using MINC’s trusted physician identification infrastructure, we can help facilitate access to evidence-based medical information that supports better patient outcomes across Canada.” -- Michael Epp, Executive Director of MINC#NIMC#.

💻 #ASCOAI#: AI may save clinicians time, but efficiency is only part of the equation. At @ClevelandClinic A.I. Summit, panelists examined how AI could affect clinical judgment, training, workload, and clinician trust in model outputs. @jamecancerdoc 🔗

The best medical AI model in the world is now called Darwin. It is the first AI to score a perfect 100% on MedQA and it leads every mainstream benchmark in the field. STAT covers the launch.

.@OpenEvidence is leveraging a partnership with a top cancer center to bolster its oncology capabilities, adding trusted genomic interpretation expertise to its platform. The company also released a new family of medical AI models, including OpenEvidence Darwin

Today we are releasing the OpenEvidence Model Family. Our most powerful models yet, and (as of 2026) the highest scoring medical AI model family in the world on every mainstream benchmark. Osler for the hallway, Sackett for the consult, Snow for the tumor board. Every model in the family is held to the same standard of clinical accuracy. What varies is time: how long a model thinks, and how deep it searches. Three of them are available to every verified clinician starting now. The fourth is Darwin. A perfect 100% on MedQA, the first AI in history to do it. Capability at that level cuts both ways in medicine, so Darwin is in research preview, by application only, while its safeguards are validated with partners like @RareDiseases. Osler, Sackett, and Snow are live now on the web and in the iOS and Android apps.

Dr. Wachter’s point on the JAMA paper arguing AI can replace doctors: AI wins when it starts with clean clinical facts. Producing those facts is the practice of medicine. It’s the doctor who examines the patient, hears what they’re saying and what they’re leaving out, and turns a messy story into a question worth answering. OpenEvidence works because there’s a physician in front of it.

Between rooms. On rounds. Walking the corridor outside an OR. Charting one-handed during a phone call. This is where clinical questions happen. Today we're launching Voice Mode. OpenEvidence is the first multimodal medical AI: physicians can type, speak, or listen, on the same evidence base. The clinician asks a clinical question out loud. Voice Mode waits when you pause, stops when you interrupt. The answer comes back concise, peer-reviewed, and verifiable against the source. Conversation with a colleague. That was the bar. For years we've focused on the intelligence: curation, retrieval, citations. Voice Mode is the interface catching up to where physicians practice. The evidence quality doesn't change with the modality. Voice answers are shorter and shaped for listening; the references and the full written form stay in the conversation. Voice Mode is now in OpenEvidence web and mobile.

Surgical oncology evidence belongs to every physician treating cancer. The medical oncologist sequencing therapy needs to know what's resectable. The radiation oncologist planning a course needs to know what margins were achieved. The primary care physician explaining options to a newly diagnosed patient needs to know what surgical care actually involves. Today we're partnering with the Society of Surgical Oncology to bring @SocSurgOnc clinical content and educational resources into OpenEvidence. The partnership also launches the SSO Innovator Grant, a 24-month research award supporting surgeon-led work on AI-enabled medical knowledge and clinical decision support in surgical oncology. Applications open Summer 2026. The body of evidence in surgical oncology is growing faster than any single surgeon can track. The point of the partnership is to put that evidence in front of every physician taking care of a cancer patient, in the moment they need it.

Jake Tapper used his segment this week to tell a story about what medical AI actually does when a physician is facing a complex case with ambiguous symptoms. Daniel Nadler, founder and CEO of OpenEvidence, walked him through it. Watch.